Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...

EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in Noema Pharma ("the Company"). The clinical-stage biotech company headquartered in Basel, Switzerland is developing a ...

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Noema was founded in 2019 with a seed investment from Sofinnova partners and is led by chief executive Luigi Costa, former CEO of Nordic Nanovector and a senior executive at Onyx Pharma ...

Swiss biotech Noema has raised 54 million Swiss francs ... four phase 2 drugs brought in from Roche after the big Swiss pharma decided somebody else should take the risk of developing them.

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. PurpleLab® stands out from ...

This week on Pipeline Moves, we kick off by looking at a Phase II trial of Noema Pharma’s NOE-105 in stuttering which completed. Meanwhile, Lyvgen Biopharma terminated a trial of its pipeline ...

BASEL, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study ...